Neoantigen DNA vaccine + Durvalumab
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Mar 30, 2022 → Sep 30, 2029
NCT ID
NCT04397003About Neoantigen DNA vaccine + Durvalumab
Neoantigen DNA vaccine + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Extensive-stage Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04397003. Target conditions include Extensive-stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04397003 | Phase 2 | Active |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer